Expression of MUC apomucins in normal pancreas and pancreatic tumours.

@article{Terada1996ExpressionOM,
  title={Expression of MUC apomucins in normal pancreas and pancreatic tumours.},
  author={Takuro Terada and Tetsuo Ohta and Motoko Sasaki and Yasuni Nakanuma and Young Ju Kim},
  journal={The Journal of pathology},
  year={1996},
  volume={180 2},
  pages={160-5}
}
The epithelial expression of apomucins MUC1, MUC2, MUC3, and MUC5/6 was examined in normal pancreas and in pancreatic lesions, using immunohistochemical methods. In normal pancreas (n = 5), MUC1 apomucin was expressed in ducts and some acini, but there was no expression of MUC2, MUC3, or MUC5/6. In chronic pancreatitis (n = 5), MUC1 apomucin was expressed, but expression of the other apomucins was not noted. However, mucous hyperplastic foci of pancreatic ducts expressed MUC5/6 apomucin in 2/5… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis , while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation .
All Topics